CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Theseus Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Theseus Pharmaceuticals Inc
314 Main Street, Suite 04-200
Phone: (857) 400-9491p:857 400-9491 CAMBRIDGE, MA  02142  United States Fax: (302) 636-5454f:302 636-5454
This company ceased filing statements with the SEC on 2/26/2024.
On 2/13/2024, the Company was acquired by Concentra Biosciences, LLC.
This company is no longer actively traded on any major stock exchange.
Business Summary
Theseus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on treating cancer patients through the discovery, development, and commercialization of targeted therapies. Its development programs are designed to address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. It also focused on tyrosine kinase inhibitors (TKIs), which is rooted in the critical role that tyrosine kinases play in the development of cancer. It develops pan-variant kinase inhibitors-inhibitors that target cancer-causing and drug resistance mutations in clinically protein kinases. Its product candidate, THE-630, is a pan-variant inhibitor of all classes of activating and resistance mutations of the KIT kinase for the treatment of GIST, a type of cancer often characterized by oncogenic activation of KIT. It is also developing THE-349, a selective epidermal growth factor receptor inhibitor for the treatment of non-small cell lung cancer.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202312/31/2022YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research
2836 Biological products, except diagnostic substances
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board, Co-Founder Iain D.Dukes 64 5/1/2021 5/1/2021
President, Chief Financial Officer, Director Bradford D.Dahms 35 12/7/2023 5/1/2021
Co-Founder, Chief Scientific Officer Victor M.Rivera 58
5 additional Officers and Directors records available in full report.

Business Names
Business Name
Theseus Securities Corporation
THRX

General Information
Number of Employees: 38 (As of 2/28/2023)
Outstanding Shares: 44,649,172 (As of 12/18/2023)
Shareholders: 8
Stock Exchange: NASD
Federal Tax Id: 830712806
Fax Number: (302) 636-5454


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, April 19, 2024